SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

Cell-free DNA (cfDNA) can act as a powerful biomarker for cancer research, from disease onset to therapy selection and minimal residual disease (MRD) measurement. Next-generation sequencing (NGS) has ...

High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance Library preparation kit adds to Twist’s portfolio of tools to ...

Cell-free DNA (cfDNA) library preparation is fundamental for successful and efficient next-generation sequencing (NGS) workflows. Researchers apply these techniques to a wide range of platforms, ...